查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790317

照護現場藥物濫用檢測市場規模、佔有率和趨勢分析報告：按產品、樣本類型、技術、最終用途、地區和細分市場進行預測，2025 年至 2033 年

Point Of Care Drug Of Abuse Testing Market Size, Share & Trends Analysis Report By Product (Immunoassay Test Strips And Cassettes, Oral Fluid Testing Kits), By Sample Type, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 136 Pages | 商品交期: 2-10個工作天內

價格

照護現場（POC）藥物濫用（DOA）檢測市場概覽

2024 年全球 POC 藥物濫用檢測市場規模估計為 10.8 億美元，預計到 2033 年將達到 24.5 億美元，2025 年至 2033 年期間的複合年成長率為 9.62%。 POC 測試包括尿液、唾液、呼吸和汗液試劑套件，可在樣本採集時快速提供結果，無需複雜的實驗室基礎設施。

這些工具擴大被應用於臨床環境、路邊執法、學校甚至家庭，成為全球公共衛生和安全策略的重要組成部分。技術進步顯著提高了 POC DOA 檢測設備的準確性、速度和易用性。基於免疫測量測定的測試條、可攜式分析儀和數位閱讀器的開發，可以用最少的樣品處理快速獲得結果。人工智慧和機器學習開始被整合到一些測試平台中，以幫助解釋結果並減少操作員錯誤。口腔液和汗液測試等非侵入性採樣方法正在提高使用者的依從性和隱私性。此外，新設備現在支援多面板藥物測試，可以同時檢測多種物質，包括鴉片類藥物、大麻、古柯鹼、安非他命和苯二氮平類藥物。這種技術創新在急診、警察局和復健中心等需要快速決策的環境中至關重要。診斷技術的小型化和連接性的改善（包括智慧型手機整合和藍牙資料登錄）使得這些工具更易於使用和方便用戶使用，從而刺激了專業市場和消費者市場的採用。

政府法規和職場安全措施是 POC DOA 檢測市場的主要驅動力。在美國等國家，聯邦法令要求對交通運輸、航空和醫療保健等安全關鍵產業進行藥物篩檢。這導致了即時檢驗 (POC)檢測套組可提供快速篩檢，除非發現陽性結果，否則無需實驗室確認。路邊藥物檢測計劃，特別是在大麻使用合法化的司法管轄區，也在推動對準確和攜帶式 POC 設備的需求。此外，學校毒品預防計劃和軍事招募流程擴大採用快速篩檢方法，以儘早阻止和發現藥物使用。在歐洲和亞洲部分地區，職場安全法和反興奮劑措施正在不斷發展，支持更廣泛的實施。這些框架不僅促進公共，而且還對可靠、經濟高效且易於使用的測試解決方案產生了穩定的需求，這些解決方案可以部署在各種分散式環境中。

隨著人們對隱私、便利性和自我監測的需求日益成長，居家 DOA 檢測的需求顯著增加。這些套件讓人們在私密環境中使用唾液、尿液或毛髮樣本對自己或他人進行檢測。隨著消費者和醫療保健提供者尋求遠端監測自身健康狀況的方法，COVID-19 疫情進一步加速了自我檢測模式的普及。遠距遠端醫療服務也為接受成癮治療和疼痛管理的患者提供了這些套件，從而增強了護理的連續性。

目錄

第 1 章。照護現場藥物濫用檢測市場：調查方法與範圍

第 2 章照護現場藥物濫用檢測市場：執行摘要

  • 市場概述
  • 產品與應用簡介
  • 測試類型簡介
  • 競爭格局簡介

第3章照護現場藥物濫用檢測市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素分析
    • 藥物濫用率上升
    • 檢測設備的技術進步
    • 對分佈式測驗的興趣日益濃厚
  • 市場限制因素分析
    • 假陽性/假陰性的風險
    • 監管和報銷挑戰
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章照護現場藥物濫用檢測市場：產品、預測與趨勢分析

  • 照護現場藥物濫用檢測市場：產品差異分析
  • 免疫檢測條和測試盒
  • 口腔液體檢測套組
  • 呼吸分析儀
  • 尿液收集杯
  • 數位/可攜式分析儀

第5章照護現場藥物濫用檢測市場：按樣本類型進行的估算和趨勢分析

  • 照護現場藥物濫用檢測市場：樣本類型變異分析
  • 尿
  • 唾液（口腔液體）
  • 呼吸
  • 血
  • 汗水/頭髮

第6章：照護現場藥物濫用檢測市場（按技術、估算和趨勢分析）

  • 照護現場藥物濫用檢測市場：技術變革分析
  • 橫向流動化驗（LFA）
  • 層析法免疫檢測
  • 酵素免疫分析法（ELISA）
  • 質譜法（可攜式或混合式 POC 裝置）

第7章照護現場藥物濫用檢測市場：按最終用途的估計和趨勢分析

  • 照護現場藥物濫用檢測市場：最終用途變異分析
  • 醫院和急診部
  • 職場和職業健康中心
  • 居家醫療和遠端用戶
  • 其他

第8章照護現場藥物濫用檢測市場：區域業務分析

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第9章 競爭態勢

  • 公司分類
  • 戰略地圖
    • 新產品發布
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 主要企業市場佔有率分析（2024年）
  • 公司熱圖分析
  • 公司簡介
    • ABBOTT
    • QUEST DIAGNOSTICS
    • THERMO FISHER SCIENTIFIC
    • ORASURE TECHNOLOGIES
    • SIEMENS HEALTHINEERS
    • F. HOFFMANN-LA ROCHE LTD.
    • Dragerwerk AG & Co. KGaA
    • LABCORP（LABORATORY CORPORATION OF AMERICA HOLDINGS）
    • PREMIER BIOTECH, INC.
Product Code: GVR-4-68040-662-7

Point Of Care Drug Of Abuse Testing Market Summary

The global point of care drug of abuse testing market size was estimated at USD 1.08 billion in 2024 and is projected to reach USD 2.45 billion by 2033, growing at a CAGR of 9.62% from 2025 to 2033, due to increasing substance misuse worldwide and the urgent need for rapid, decentralized drug testing solutions. POC testing, which includes urine, saliva, breath, and sweat-based kits, provides rapid results at the site of sample collection, eliminating the need for complex lab infrastructure.

These tools are increasingly being adopted in clinical settings, roadside enforcement, schools, and even at home, making them a key component in public health and safety strategies globally. Technological advancements are significantly enhancing the accuracy, speed, and usability of POC DOA testing devices. The development of immunoassay-based test strips, portable analyzers, and digital readers enables fast results with minimal sample handling. AI and machine learning are beginning to integrate into some testing platforms, assisting in result interpretation and reducing operator error. Non-invasive sampling methods, such as oral fluid and sweat-based testing, are improving user compliance and privacy. In addition, newer devices now support multi-panel drug testing, enabling simultaneous detection of multiple substances such as opioids, cannabis, cocaine, amphetamines, and benzodiazepines. These innovations are crucial in settings where quick decision-making is essential-such as emergency departments, law enforcement operations, and rehabilitation centers. The miniaturization of diagnostic technology and improved connectivity features, including smartphone integration and Bluetooth-enabled data logging, are making these tools more accessible and user-friendly, driving adoption in both professional and consumer markets.

Government regulations and workplace safety initiatives are key drivers in the expansion of the POC DOA testing market. In countries such as the U.S., federal mandates require drug screening for safety-sensitive industries such as transportation, aviation, and healthcare. This has led to widespread use of on-site testing kits that provide rapid screening without needing laboratory confirmation unless a positive result arises. Roadside drug testing programs, particularly in jurisdictions with legalized cannabis use, are also boosting demand for accurate and mobile POC devices. Moreover, school drug prevention programs and military recruitment processes increasingly incorporate quick screening methods to deter and identify drug use early. In Europe and parts of Asia, evolving workplace safety laws and anti-doping initiatives are supporting broader implementation. These frameworks not only promote public safety but also create a steady demand for reliable, cost-effective, and easy-to-use testing solutions that can be deployed in a range of decentralized environments.

The growing demand for privacy, convenience, and self-monitoring has led to a significant rise in at-home DOA testing. These kits allow individuals to test themselves or others in private settings using saliva, urine, or hair samples. The COVID-19 pandemic further accelerated the adoption of self-testing models, as consumers and healthcare providers looked for ways to monitor health remotely. Telehealth services have incorporated these kits for patients undergoing addiction treatment or pain management, enhancing continuity of care.

Global Point of Care Drug of Abuse Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point of care drug of abuse testing market based on product, technology, sample type, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassay Test Strips and Cassettes
  • Oral Fluid Testing Kits
  • Breath Analyzers
  • Urine Collection Cups
  • Digital/Portable Analyzers
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Lateral Flow Assay (LFA)
  • Chromatographic Immunoassays
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Mass Spectrometry (portable or hybrid POC units)
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Emergency Departments
  • Workplace & Occupational Health Center
  • Home Care & Remote Users
  • Others
  • Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Urine
  • Saliva (Oral Fluid)
  • Breath
  • Blood
  • Sweat/Hair
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Point of Care Drug of Abuse (DOA) Testing Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Application Segment
      • 1.1.1.3. Test Type segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Point of Care Drug of Abuse (DOA) Testing Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Application Snapshot
  • 2.3. Test Type Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Point of Care Drug of Abuse (DOA) Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising Substance Abuse Rates
    • 3.4.2. Technological Advancements in Testing Devices
    • 3.4.3. Growing Preference for Decentralized Testing
  • 3.5. Market Restraint Analysis
    • 3.5.1. Risk of False Positives/Negatives
    • 3.5.2. Regulatory and Reimbursement Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Point of Care Drug of Abuse (DOA) Testing Market: Product Estimates & Trend Analysis

  • 4.1. Point of Care Drug of Abuse (DOA) Testing Market: Product Movement Analysis
  • 4.2. Immunoassay Test Strips and Cassettes
  • 4.3. Oral Fluid Testing Kits
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Breath Analyzers
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Urine Collection Cups
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Digital/Portable Analyzers
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Estimates & Trend Analysis

  • 5.1. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Movement Analysis
  • 5.2. Urine
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Saliva (Oral Fluid)
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Breath
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Blood
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Sweat/Hair
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Point of Care Drug of Abuse (DOA) Testing Market: Technology Estimates & Trend Analysis

  • 6.1. Point of Care Drug of Abuse (DOA) Testing Market: Technology Movement Analysis
  • 6.2. Lateral Flow Assay (LFA)
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Chromatographic Immunoassays
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Mass Spectrometry (portable or hybrid POC units)
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Point of Care Drug of Abuse (DOA) Testing Market: End Use Estimates & Trend Analysis

  • 7.1. Point of Care Drug of Abuse (DOA) Testing Market: End Use Movement Analysis
  • 7.2. Hospitals & Emergency Departments
    • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Workplace & Occupational Health Center
    • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Home Care & Remote Users
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Others
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Point of Care Drug of Abuse (DOA) Testing Market: Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America Point of Care Drug of Abuse (DOA) Testing Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Reimbursement Scenario
      • 8.2.2.5. Competitive Scenario
    • 8.2.3. Canada
      • 8.2.3.1. Canada Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Reimbursement Scenario
      • 8.2.3.5. Competitive Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Reimbursement Scenario
      • 8.2.4.5. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Scenario
      • 8.3.2.5. Competitive Scenario
    • 8.3.3. Germnay
      • 8.3.3.1. Germany Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Scenario
      • 8.3.3.5. Competitive Scenario
    • 8.3.4. Spain
      • 8.3.4.1. Spain Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Reimbursement Scenario
      • 8.3.4.5. Competitive Scenario
    • 8.3.5. France
      • 8.3.5.1. France Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Reimbursement Scenario
      • 8.3.5.5. Competitive Scenario
    • 8.3.6. Italy
      • 8.3.6.1. Italy Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Reimbursement Scenario
      • 8.3.6.5. Competitive Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Reimbursement Scenario
      • 8.3.7.5. Competitive Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Reimbursement Scenario
      • 8.3.8.5. Competitive Scenario
    • 8.3.9. Norway
      • 8.3.9.1. Norway Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Reimbursement Scenario
      • 8.3.9.5. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. Competitive Scenario
    • 8.4.3. China
      • 8.4.3.1. China Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Competitive Scenario
    • 8.4.4. India
      • 8.4.4.1. India Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Competitive Scenario
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Scenario
      • 8.4.5.5. Competitive Scenario
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Scenario
      • 8.4.6.5. Competitive Scenario
    • 8.4.7. Australia
      • 8.4.7.1. Australia Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Scenario
      • 8.4.7.5. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.5.2.2. Key Country Dynamics
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. Competitive Scenario
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.5.3.2. Key Country Dynamics
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Competitive Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. Competitive Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. NEW PRODUCT LAUNCH
    • 9.2.2. PARTNERSHIPS
    • 9.2.3. ACQUISITION
    • 9.2.4. COLLABORATION
    • 9.2.5. FUNDING
  • 9.3. Key Company Market Share Analysis, 2024
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. ABBOTT
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. QUEST DIAGNOSTICS
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. THERMO FISHER SCIENTIFIC
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. ORASURE TECHNOLOGIES
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. SIEMENS HEALTHINEERS
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. F. HOFFMANN-LA ROCHE LTD.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Dragerwerk AG & Co. KGaA
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. LABCORP (LABORATORY CORPORATION OF AMERICA HOLDINGS)
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. PREMIER BIOTECH, INC.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Point of Care Drug of Abuse (DOA) Testing Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
  • Table 5 Global Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 6 Global Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 7 Global Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 8 North America Point of Care Drug of Abuse (DOA) Testing Market, By Country, 2021 - 2033 (USD Million)
  • Table 9 North America Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
  • Table 10 North America Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 11 North America Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 12 North America Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 13 U.S. Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 14 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 15 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Canada Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
  • Table 18 Canada Point of Care Drug of Abuse (DOA) Testing Market, by Product, 2021 - 2033 (USD Million)
  • Table 19 Canada Point of Care Drug of Abuse (DOA) Testing Market, by Technology, 2021 - 2033 (USD Million)
  • Table 20 Canada Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 21 Mexico Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 23 Mexico Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 24 Mexico Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 25 Europe Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 27 Europe Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 28 Europe Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Europe Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 UK Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 31 UK Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 32 UK Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 33 UK Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34 Germany Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 35 Germany Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 36 Germany Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 37 Germany Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 38 France Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 39 France Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 40 France Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 France Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Italy Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 44 Italy Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 45 Italy Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 46 Spain Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 47 Spain Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 48 Spain Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 49 Spain Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 50 Sweden Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 51 Sweden Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 52 Sweden Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 53 Sweden Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 54 Norway Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 55 Norway Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 56 Norway Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 Norway Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 Denmark Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 59 Denmark Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 60 Denmark Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 61 Denmark Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 Japan Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 68 Japan Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 69 Japan Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 70 Japan Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 71 China Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 72 China Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 73 China Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 74 China Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 75 India Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 76 India Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 77 India Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 78 India Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 79 Australia Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 80 Australia Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 81 Australia Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 82 Australia Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 83 Thailand Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 84 Thailand Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 85 Thailand Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 Thailand Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 South Korea Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 88 South Korea Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 89 South Korea Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 90 South Korea Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 91 Latin America Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 94 Latin America Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Latin America Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 96 Brazil Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 97 Brazil Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 98 Brazil Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 99 Brazil Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 100 Argentina Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 101 Argentina Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 102 Argentina Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 103 Argentina Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 104 MEA Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
  • Table 105 MEA Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 106 MEA Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 107 MEA Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 108 MEA Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 109 South Africa Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 110 South Africa Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 111 South Africa Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 112 South Africa Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 117 UAE Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
  • Table 118 UAE Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 119 UAE Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 120 UAE Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD)
  • Table 122 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
  • Table 124 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global point of care drug of abuse (DOA) testing market - Key market driver analysis
  • Fig. 7 Global point of care drug of abuse (DOA) testing market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global point of care drug of abuse (DOA) testing market - Porter's analysis
  • Fig. 10 Global point of care drug of abuse (DOA) testing market - PESTEL analysis
  • Fig. 11 Global point of care drug of abuse (DOA) testing market product outlook key takeaways
  • Fig. 12 Global point of care drug of abuse (DOA) testing market: Product movement analysis
  • Fig. 13 Immunoassay Test Strips and Cassettes
  • Fig. 14 Oral Fluid Testing Kits market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Breath Analyzers market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Urine Collection Cups market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Digital/Portable Analyzers market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Global point of care drug of abuse (DOA) testing market sample type outlook key takeaways
  • Fig. 19 Global point of care drug of abuse (DOA) testing market: sample type movement analysis
  • Fig. 20 Urine market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Saliva (Oral Fluid) market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Breath market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Blood market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Sweat/Hair market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Global point of care drug of abuse (DOA) testing market technology outlook key takeaways
  • Fig. 26 Global point of care drug of abuse (DOA) testing market: technology movement analysis
  • Fig. 27 Lateral Flow Assay (LFA) market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Chromatographic Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Enzyme-Linked Immunosorbent Assay (ELISA) market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Mass Spectrometry (portable or hybrid POC units) market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 Global point of care drug of abuse (DOA) testing market end use outlook key takeaways
  • Fig. 32 Global point of care drug of abuse (DOA) testing market: sample type movement analysis
  • Fig. 33 Urine market estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Global point of care drug of abuse (DOA) testing market: Regional movement analysis
  • Fig. 36 North America point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 39 Mexico point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 40 Europe point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 41 UK point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 43 France point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 44 Spain point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 46 Denmark point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 51 China point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 52 India point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 53 South Korea point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 54 Australia point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 55 Thailand point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 56 Latin America point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 57 Brazil point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 58 Argentina point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 59 MEA point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 60 South Africa point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 61 Saudi Arabia point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 62 UAE point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 63 Kuwait point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
  • Fig. 64 Strategy framework